DOI:
10.1055/s-00000030
Der Klinikarzt
LinksClose Window
References
Iveson T, Donehower RC, Davidenko I et al.
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
Lancet Oncol 2014;
14: 1470-2045
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.